1,053,015 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Alyeska Investment Group L.P.

Key Points

• Alyeska Investment Group purchased 1,053,015 Amylyx Pharmaceuticals shares worth approximately $18.9 million, acquiring a 0.95% stake. Institutional investors collectively own 95.84% of the company.
• Amylyx reported a quarterly loss of $0.39 per share, missing the $0.36 consensus estimate; analysts expect a full-year loss of $1.48 per share.
• Analyst sentiment remains generally positive, with an average “Buy” rating and a $36.50 consensus price target, though ratings range from “Strong Buy” to “Sell.”

Alyeska Investment Group L.P. purchased a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 1,053,015 shares of the company's stock, valued at approximately $18,912,000. Alyeska Investment Group L.P. owned about 0.95% of Amylyx Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Millennium Management LLC lifted its stake in Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company's stock worth $10,910,000 after purchasing an additional 2,487,617 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Amylyx Pharmaceuticals by 7.7% during the first quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company's stock valued at $7,090,000 after buying an additional 143,065 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Amylyx Pharmaceuticals by 62.7% during the second quarter. JPMorgan Chase & Co. now owns 87,989 shares of the company's stock valued at $564,000 after buying an additional 33,920 shares during the last quarter. Legal & General Group Plc purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth approximately $47,000. Finally, Rhumbline Advisers purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter worth approximately $645,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Stock Performance

Amylyx Pharmaceuticals stock opened at $33.75 on Tuesday. The company has a market capitalization of $3.76 billion, a PE ratio of -23.60 and a beta of -0.21. The company has a 50 day moving average price of $22.88 and a 200-day moving average price of $17.65. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $9.15 and a fifty-two week high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current year.

Insider Buying and Selling at Amylyx Pharmaceuticals

In related news, insider Gina Mazzariello sold 15,000 shares of the company's stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $18.32, for a total value of $274,800.00. Following the completion of the sale, the insider directly owned 194,090 shares of the company's stock, valued at $3,555,728.80. This represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on AMLX shares. Wolfe Research raised Amylyx Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 17th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Wall Street Zen lowered Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Guggenheim lifted their target price on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a "buy" rating in a research report on Thursday, August 27th. Finally, HC Wainwright boosted their target price on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a "buy" rating in a research note on Tuesday, August 18th. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Amylyx Pharmaceuticals has an average rating of "Buy" and a consensus price target of $36.50.

Amylyx Pharmaceuticals Profile

Want to see what other hedge funds are holding AMLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.